28/02/2022 – AB Science announces today that it reached an agreement with a historical investor on a financing of USD 8.5 million through the issuance of bonds convertible into new ordinary shares with attached warrants Download PDF Post navigationPreviousPrevious post:AB Science will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment ALS in Canada and to provide an update on its clinical program in all indicationsNextNext post:Webcast Presentation – Masitinib filing in the treatment of ALS in Canada and update on AB Science clinical program in all indicationsRelated PostsAnnual financial results as of 31 December, 2021April 29, 2022Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating masitinib in combination with isoquercetin in Covid-19April 28, 2022Communication from AB Science following the decision of the Enforcement Committee of the French market regulator (AMF)March 29, 2022Webcast Presentation – Masitinib filing in the treatment of ALS in Canada and update on AB Science clinical program in all indicationsFebruary 28, 2022AB Science will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment ALS in Canada and to provide an update on its clinical program in all indicationsFebruary 24, 2022Publication of the masitinib positive pivotal phase 3 trial in progressive forms of multiple sclerosis in the journal Neurology® Neuroimmunology & NeuroinflammationFebruary 22, 2022
Positive recommendation of the Data and Safety Monitoring Board to continue the Phase 2 study evaluating masitinib in combination with isoquercetin in Covid-19April 28, 2022
Communication from AB Science following the decision of the Enforcement Committee of the French market regulator (AMF)March 29, 2022
Webcast Presentation – Masitinib filing in the treatment of ALS in Canada and update on AB Science clinical program in all indicationsFebruary 28, 2022
AB Science will host a live webcast on February 28, 2022 to provide details on the masitinib filing in the treatment ALS in Canada and to provide an update on its clinical program in all indicationsFebruary 24, 2022
Publication of the masitinib positive pivotal phase 3 trial in progressive forms of multiple sclerosis in the journal Neurology® Neuroimmunology & NeuroinflammationFebruary 22, 2022
